These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25645864)

  • 1. Can circulating tumor cells predict resistance in metastatic breast cancer?
    Mathew A; Brufsky AM; Davidson NE
    Clin Cancer Res; 2015 Jun; 21(11):2421-3. PubMed ID: 25645864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.
    Paoletti C; Muñiz MC; Thomas DG; Griffith KA; Kidwell KM; Tokudome N; Brown ME; Aung K; Miller MC; Blossom DL; Schott AF; Henry NL; Rae JM; Connelly MC; Chianese DA; Hayes DF
    Clin Cancer Res; 2015 Jun; 21(11):2487-98. PubMed ID: 25381338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Marker Genes for Real-Time PCR-based Detection of Circulating Tumour Cells from Blood of Breast Cancer Patients.
    Kölbl AC; Bräuer D; Hutter S; Rack B; Friese K; Jeschke U; Andergassen U
    Anticancer Res; 2016 Jun; 36(6):3211-6. PubMed ID: 27272851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy.
    Aaltonen KE; Novosadová V; Bendahl PO; Graffman C; Larsson AM; Rydén L
    Oncotarget; 2017 Jul; 8(28):45544-45565. PubMed ID: 28489591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
    Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
    Schramm A; Friedl TW; Schochter F; Scholz C; de Gregorio N; Huober J; Rack B; Trapp E; Alunni-Fabbroni M; Müller V; Schneeweiss A; Pantel K; Meier-Stiegen F; Hartkopf A; Taran FA; Wallwiener D; Janni W; Fehm T
    Arch Gynecol Obstet; 2016 Feb; 293(2):271-81. PubMed ID: 26354331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies.
    Tewes M; Aktas B; Welt A; Mueller S; Hauch S; Kimmig R; Kasimir-Bauer S
    Breast Cancer Res Treat; 2009 Jun; 115(3):581-90. PubMed ID: 18679793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
    BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
    Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of circulating tumor cells and its clinical value for different stages and various subtypes of breast cancer].
    Li L; Liu Y; Zhang S; Wang T; Bian L; Wu S; Song S; Liu B; Jiang Z
    Zhonghua Yi Xue Za Zhi; 2014 Sep; 94(36):2812-5. PubMed ID: 25534097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Are the new breast cancer subtypes (luminal A, B etc.) of practical impact? Yes].
    Stöger H
    Dtsch Med Wochenschr; 2013 Oct; 138(41):2096. PubMed ID: 24085364
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer.
    Smerage JB; Budd GT; Doyle GV; Brown M; Paoletti C; Muniz M; Miller MC; Repollet MI; Chianese DA; Connelly MC; Terstappen LW; Hayes DF
    Mol Oncol; 2013 Jun; 7(3):680-92. PubMed ID: 23538216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral Heterogeneity in Breast Cancer: A Comparison of Primary and Metastatic Breast Cancers.
    Shi YJ; Tsang JY; Ni YB; Tse GM
    Oncologist; 2017 Apr; 22(4):487-490. PubMed ID: 28341760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.
    Wülfing P; Borchard J; Buerger H; Heidl S; Zänker KS; Kiesel L; Brandt B
    Clin Cancer Res; 2006 Mar; 12(6):1715-20. PubMed ID: 16551854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Are the new breast cancer subtypes (luminal A, B etc.) of practical impact? No].
    Gampenrieder SP
    Dtsch Med Wochenschr; 2013 Oct; 138(41):2097. PubMed ID: 24085365
    [No Abstract]   [Full Text] [Related]  

  • 17. Gene profiling and circulating tumor cells as biomarker to prognostic of patients with locoregional breast cancer.
    Kuniyoshi RK; Gehrke Fde S; Alves BC; Vilas-Bôas V; Coló AE; Sousa N; Nunes J; Fonseca FL; Del Giglio A
    Tumour Biol; 2015 Sep; 36(10):8075-83. PubMed ID: 25976504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients.
    Giordano A; Giuliano M; De Laurentiis M; Eleuteri A; Iorio F; Tagliaferri R; Hortobagyi GN; Pusztai L; De Placido S; Hess K; Cristofanilli M; Reuben JM
    Breast Cancer Res Treat; 2011 Sep; 129(2):451-8. PubMed ID: 21710134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.
    Beije N; Onstenk W; Kraan J; Sieuwerts AM; Hamberg P; Dirix LY; Brouwer A; de Jongh FE; Jager A; Seynaeve CM; Van NM; Foekens JA; Martens JW; Sleijfer S
    Neoplasia; 2016 Nov; 18(11):647-653. PubMed ID: 27764697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Tumor Cells.
    Paoletti C; Hayes DF
    Adv Exp Med Biol; 2016; 882():235-58. PubMed ID: 26987538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.